Screener
R&D at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:04 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336682
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | $23,768 | $27,217 | $51,379 | $49,336 |
| Selling, general and administrative | 21,925 | 15,640 | 38,093 | 31,324 |
| Total operating expenses | 45,693 | 42,857 | 89,472 | 80,660 |
| Loss from operations | (45,693) | (42,857) | (89,472) | (80,660) |
| Other income, net: | ||||
| Interest income | 2,323 | 1,960 | 4,893 | 4,191 |
| Other expense, net | (53) | (546) | (128) | (881) |
Item 1. Financial Statements.
FAQ
- What is Amylyx Pharmaceuticals, Inc.'s R&D?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported R&D of $23.77M in Q2 2026.
- How has Amylyx Pharmaceuticals, Inc.'s R&D changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s R&D decreased by 12.7% year-over-year, from $27.22M to $23.77M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s R&D?
- Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s R&D has grown at a 19.7% compound annual growth rate (CAGR), from $44.04M to $90.4M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Amylyx Pharmaceuticals, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude